EC
KLDO

EcoR1 Capital’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

EcoR1 Capital’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-31,374
Closed -$233K – 63
2020
Q2 		$233K Buy
+31,374
New +$210K 0.02% 47

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

EcoR1 Capital's KLDO Position: Q3 2020 in Review

EcoR1 Capital sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2020, closing a stake of 31,374 shares — an estimated $233K sold.

EcoR1 Capital first reported a position in KLDO in Q2 2020 and held it in 1 quarter. The position peaked at $233K in Q2 2020. 56 funds tracked by Wall St. Rank hold KLDO as of Q3 2020.

  • EcoR1 Capital reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • EcoR1 Capital sold 31,374 Kaleido Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $233K.
  • EcoR1 Capital first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • EcoR1 Capital's Kaleido Biosciences, Inc. Common Stock position peaked at $233K in Q2 2020.
  • 56 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2020.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.